ethyl 3-cyano-5-(phenylthio)indol-2-ylcarbamate

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: ethyl 3-cyano-5-(phenylthio)indol-2-ylcarbamate
• 英文别名: ethyl N-(3-cyano-5-phenylsulfanyl-1H-indol-2-yl)carbamate
• 化学式: C₁₈H₁₅N₃O₂S
• 分子量: 337.402
• InChiKey: LPJPYBCBYNFYCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-amino-3-cyano-5-(phenylthio)indole 、 乙基苯基碳酸脂 以 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 生成 ethyl 3-cyano-5-(phenylthio)indol-2-ylcarbamate
  参考文献：
  名称：

  Amino, cyano phenylthio or phenoxyl indole derivatives

  摘要：

  本发明涉及具有抗癌活性的吲哚衍生物。根据本发明，提供了式I的吲哚衍生物：##STR1## 其中X是氧或硫原子，Ra是苯基基团，可选地被一或两个从卤素原子和1-6C烷基、1-6C烷氧基和三氟甲基基团中选择的基团取代，Rb是氢原子或2-6C烷氧羰基基团。还描述了制造工艺和制药组合物。

  公开号：

  US04533672A1

文献信息

• Indole derivatives with vascular damaging activity
  申请人：——

  公开号：US20030216356A1

  公开（公告）日：2003-11-20

  The invention provides a compound of Formula (I) wherein: R 1 and R 2 are independently selected from hydrogen, halogen, —CN, a hydrocarbyl group or a group of Formula (II); wherein W is aryl or a heterocyclic group, R 4 is independently select from hydrogen, halogen, —OH, amino, alkanoylamino, —OPO 3 H 2 , or a hydrocarbyl group, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified or two R 4 groups together form an optionally substituted cyclic or heterocyclic group; X is selected from $M(y) S+—, +—O—+, —+S(O)+—, —+S(O 2 )+— and —+NH—; p is an integer from 0 to 4; and q is an integer from 1 to 4; R 3 and R 10 are independently selected from hydrogen, lower alkyl or a group of Formula (IV): wherein Y is selected from +NH+—, —$M(Y)O$M(Y)— or a bond; Z is selected from +NH+—, —+O&ngr;—, —+C(O)+— or a bond; r is an integer from 0 to 4; t is an integer from 0 to 1; R 6 is hydrogen, a hydrocarbyl group or a group of Formula (V): wherein n is an integer of from 1 to 6, and; R 7 and R 8 are independently selected from hydrogen or a hydrocarbyl group; and R 11 is hydrogen or lower alkyl; or a salt or solvate thereof; provided that: I) when R 1 is an unsubstituted phenylthio group (Ph—S—), R 2 is H, R 10 is H and R 11 is H then R 3 is neither H nor —C(O)—O—CH 2 CH 3 ; and ii) R 1 , R 2 and R 3 are not all hydrogen. Such compounds are predicted to cause the selective destruction of tumour vasculature. They may therefore be used to inhibit and/or reverse, and/or alleviate symptoms of angiogenesis and/or any disease state associated with angiogenesis. 1

  该发明提供了一个化合物，其化学式为（I），其中：R1和R2分别选自氢、卤素、—CN、烃基团或化学式（II）的基团；其中W为芳基或杂环基团，R4独立选择自氢、卤素、—OH、氨基、烷酰胺基、—OPO3H2或烃基团，其中氨基团可选择性地被氨基酸残基取代，羟基可选择性酯化，或两个R4基团共同形成一个可选择性取代的环状或杂环基团；X选自$M(y)S+—、+—O—+、—+S(O)+—、—+S(O2)+—和—+NH—；p为0至4之间的整数；q为1至4之间的整数；R3和R10独立选择自氢、较低烷基或化学式（IV）的基团：其中Y选自+NH+—、—$M(Y)O$M(Y)—或键；Z选自+NH+—、—+O&ngr;—、—+C(O)+—或键；r为0至4之间的整数；t为0或1之间的整数；R6为氢、烃基团或化学式（V）的基团：其中n为1至6之间的整数；R7和R8独立选择自氢或烃基团；R11为氢或较低烷基；或其盐或溶剂化合物；但要求：I）当R1为未取代的苯硫基团（Ph—S—）时，R2为H，R10为H且R11为H，则R3既不是H也不是—C(O)—O—CH2CH3；和II）R1、R2和R3不全为氢。预测这类化合物可能导致肿瘤血管的选择性破坏。因此，它们可以用于抑制和/或逆转和/或缓解血管生成及/或与血管生成相关的任何疾病状态的症状。
• Indole derivatives
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0107963A1

  公开（公告）日：1984-05-09

  This invention relates to indole derivatives which have anti-cancer activity. According to the invention there is provided an indole derivative of the formula I : in which X is an oxygen or sulphur atom, Ra is a phenyl radical which is optionally substituted by one or two groups selected from halogen atoms and 1-6C alkyl, 1-6C alkoxy and trifluoromethyl radicals and Rb is a hydrogen atom or a 2-6C alkoxycarbonyl radical. Manufacturing processes and pharmaceutical compositions are also described.

  本发明涉及具有抗癌活性的吲哚衍生物。根据本发明，提供了一种式 I 的吲哚衍生物： 其中 X 为氧原子或硫原子，Ra 为苯基，可任选被一或两个选自卤素原子、1-6C 烷基、1-6C 烷氧基和三氟甲基的基团取代，Rb 为氢原子或 2-6C 烷氧羰基。还描述了制造工艺和药物组合物。
• INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY
  申请人：AstraZeneca AB

  公开号：EP1289952A1

  公开（公告）日：2003-03-12
• US4533672A
  申请人：——

  公开号：US4533672A

  公开（公告）日：1985-08-06
• US7030123B2
  申请人：——

  公开号：US7030123B2

  公开（公告）日：2006-04-18